A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma

The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms Pancreatic Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

First Affiliated Hospital, Medical College of Zhejiang University

Hangzhou, Zhejiang, 310003, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pathologically confirmed PDAC
Achievement of surgical resection (including radical or palliative surgery)

Exclusion criteria

Lost to follow-up
Simultaneous presence of other tumors
Died in three months after surgery

Treatment and study plan

pancreatic cancer surgery

Procedure

Surgical resection of pancreatic cancer，including radical or palliative surgery

Primary outcomes

overall survival

Time frame: after pancreatic cancer surgery until october 31, 2020

the number of months from the date of surgery to the date of the last follow-up visit or time of death.

Secondary outcomes

disease-free survival disease-free survival disease-free survival disease-free survival

Time frame: after pancreatic cancer surgery until october 31, 2020

the number of months from the date of surgery to the date of first confirmable recurrence or death

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Registry information

Official study title

Development and Validation of a New Prognostic Score Model Combining TNM Stage With Immune Risk Factors for Postoperative Pancreatic Ductal Adenocarcinoma

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2022
First posted: Sep 21, 2022
Registry last updated: Sep 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed